Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Use With COVID-19 Vaccines

The use of vaccines against SARS-CoV-2 in patients treated with Abasaglar has not been studied.

Administration of COVID-19 Vaccines to Patients Receiving Abasaglar

Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the COVID-19 pandemic. Recently, vaccines have been developed against SARS-CoV-2 and some of them are already available.1-4

SARS-CoV-2 Vaccination With Abasaglar

The use of a SARS-CoV-2 vaccine in patients treated with Abasaglar has not been studied by Lilly.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with Abasaglar should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient and the risks and benefits of vaccination.

Possible impact of vaccination on blood glucose concentration

The International Diabetes Federation IDF states that after any vaccination the blood glucose levels might rise for a few days.5

Further resources on COVID-19 Vaccines and Diabetes

For information on COVID-19 vaccines and diabetes, please refer to

For current information on COVID-19 and COVID-19 vaccines in general, please refer to

References

1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

2. Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920-1931. https://doi.org/10.1056/NEJMoa2022483

3. COVID-19 vaccines. Centers for Disease Control and Prevention. Updated December 31, 2020. Accessed January 4, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

4. Draft landscape of COVID-19 candidate vaccines. World Health Organization (WHO). November 12, 2020. Accessed December 4, 2020. https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-19-(7).pdf?sfvrsn=a4e55ae3_2&download=true

5. International Diabetes Federation Europe. Diabetes & Coronavirus Vaccination. https://idf.org/our-network/regions-members/europe/europe-news/370-diabetes-coronavirus-vaccination.html. Accessed April 29, 2021

6. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

7. International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020

8. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Date of Last Review: January 04, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request